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Abstract: Many phenylketonuria (PKU) patients cannot adhere to the severe dietary restrictions
as advised by the European PKU guidelines, which can be accompanied by aggravated
neuropsychological impairments that, at least in part, have been attributed to brain monoaminergic
neurotransmitter deficiencies. Supplementation of large neutral amino acids (LNAA) to an unrestricted
diet has previously been shown to effectively improve brain monoamines in PKU mice of various ages.
To determine the additive value of LNAA supplementation to a liberalized phenylalanine-restricted
diet, brain and plasma monoamine and amino acid concentrations in 10 to 16-month-old adult
C57Bl/6 PKU mice on a less severe phenylalanine-restricted diet with LNAA supplementation
were compared to those on a non-supplemented severe or less severe phenylalanine-restricted diet.
LNAA supplementation to a less severe phenylalanine-restricted diet was found to improve both
brain monoamine and phenylalanine concentrations. Compared to a severe phenylalanine-restricted
diet, it was equally effective to restore brain norepinephrine and serotonin even though being less
effective to reduce brain phenylalanine concentrations. These results in adult PKU mice support the
idea that LNAA supplementation may enhance the effect of a less severe phenylalanine-restricted diet
and suggest that cerebral outcome of PKU patients treated with a less severe phenylalanine-restricted
diet may be helped by additional LNAA treatment.
Keywords: phenylketonuria; Pah-enu2 mouse model; dietary treatment; monoaminergic
neurotransmitters; large neutral amino acids; adult
1. Introduction
In phenylketonuria (PKU; McKusick 261600), mutations in the gene encoding for the hepatic
enzyme phenylalanine hydroxylase, that normally converts phenylalanine (Phe) into tyrosine, result
in toxic accumulation of Phe in blood and brain. Following this pathophysiological concept, a
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severe Phe-restricted diet has been the cornerstone of treatment over the last 65 years. In addition,
the principle of the severe Phe-restricted diet (limiting natural protein intake and supplementing
an amino acid mixture devoid of the one(s) prior to the metabolic block) has served as an example
for dietary treatment in many other inborn errors of amino acid metabolism [1]. Notwithstanding
these successes, however, even in early- and continuously treated PKU patients neuropsychological
outcome remains suboptimal [2–6], with children and adults showing some different problems [6].
The two pathophysiological mechanisms considered to be the most important in this are cerebral
Phe toxicity and monoaminergic neurotransmitter impairments [7]. The latter has been shown to
result from a combination of high brain Phe levels inhibiting tyrosine- and tryptophan hydroxylases
and insufficient brain tyrosine and tryptophan availability, the amino acid precursors of dopamine,
norepinephrine, and serotonin [8,9]. Moreover, many patients cannot adhere to the severe dietary
restrictions as the diet is socially very demanding. In consequence, these patients have plasma Phe
concentrations that are clearly above the recommended therapeutic range and can be accompanied
by several manifestations of suboptimal brain function [10,11]. Alternative treatment strategies that
particularly address these problems are, therefore, being pursued, one of these being large neutral
amino acid (LNAA) treatment [12].
Both LNAA supplementation and severe dietary Phe-restriction strive at optimal cerebral
amino acid and neurotransmitter biochemistry to optimize neurocognitive and psychosocial outcome
through nutritional intervention, but their primary biochemical treatment targets differ. Whereas
the severe Phe-restricted diet primarily aims to reduce plasma Phe concentrations in order to restore
brain biochemistry, LNAA supplementation primarily aims to normalize brain amino acid and
neurotransmitter concentrations by outcompeting brain Phe and favouring brain non-Phe LNAA
uptake through increased plasma non-Phe LNAA availability [13]. Several studies have investigated
this concept of LNAA treatment both in PKU patients and mice, all using different compositions of
LNAA supplementation, protocols, and outcome measures [14–22].
To systematically investigate the biochemical working mechanisms and optimal composition
of LNAA treatment for PKU patients, we have taken advantage of the existence of the PKU mouse
model, which allows for direct measurement of brain amino acid and neurotransmitter concentrations.
Previously, we first showed that LNAA treatment can: (1) reduce brain Phe, (2) increase brain non-Phe
LNAA, and -most effectively- (3) increase brain neurotransmitter concentrations [23]. Secondly,
we demonstrated that each of these brain biochemical treatment effects requires another optimal
composition of LNAA supplementation [8]. Thirdly, we showed that LNAA treatment in adult PKU
mice on its own is equally effective as a severe Phe-restricted diet to restore brain neurotransmitter
concentrations, even though brain Phe concentrations remain significantly higher [9]. In all these
studies, LNAA were supplemented to an unrestricted diet. One of the remaining questions is, therefore,
whether and how LNAA treatment can be used to improve outcomes in PKU patients who cannot get
their Phe concentrations within the recommended target range. In response to this clinical question
and building on our previous studies on LNAA treatment in PKU mice, the present study aimed to
determine the additive value of LNAA supplementation to a less severe Phe-restricted diet on brain
neurotransmitter as well as brain and plasma amino acid concentrations in comparison to a severe
Phe-restricted diet in adult PKU mice.
2. Material and Methods
2.1. Animals
C57Bl/6 Pah-enu2 mice had originally been kindly provided by Prof. B. Thöny from the division of
Clinical Chemistry and Biochemistry, University Children’s Hospital, Zurich, Switzerland to establish
our own breeding line. From heterozygous (HTZ, +/−) mating, we obtained wild-type (WT, +/+), HTZ,
and PKU (−/−) mice of both sexes. After weaning at four weeks of age, genetic characterization was
performed by quantitative polymerase chain reaction (PCR) analysis on DNA extracted from ear tissue
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and animals were housed individually at 21 ± 1 ◦C on a 12-h light–dark cycle. Water and AM-II food
pellets (Arie Block BV, Woerden, The Netherlands) were offered ad libitum. Animals were individually
housed from the start of the experiment. In total, we used 10 WT (5 male, 5 female) and 30 PKU
(15 male, 15 female). Median age at inclusion was 56 weeks (range 46–70 weeks). All procedures and
treatments were carried out in strict accordance with the recommendations mentioned in the Guide for
the Care and Use of Laboratory Animals of the National Institutes of Health. The Institutional Animal
Care and Use Committee of the University of Groningen approved the experimental protocol before
initiation of the study.
2.2. Experimental Design
Animals were included in the experiment at age 10–16 months. PKU mice born from different
mothers were assigned to one of three different dietary treatment groups, balanced for sex and age.
Body weight and food intake were measured daily during the first week of the experiment and
weekly during the 5 weeks thereafter. After 6 weeks of dietary treatment, animals were euthanized by
combined heart puncture and decapitation under inhalation-anesthetics with isoflurane.
2.3. Experimental Diets
The protein contents of the experimental diets are presented in Figure 1. The basal diet was
AIN-93M [24], which was administered in unadjusted form to the WT control group. The severe
and less severe Phe-restricted diets were produced by reducing the amount of casein by 75% and
33% compared to the basal diet, respectively. This was compensated for by a synthetic amino acid
mixture devoid of Phe, plus 20% extra for the assumed protein conversion factor [25], at the expense
of cornstarch. The less severe Phe-restricted diet with LNAA was produced by adding LNAA to the
33% Phe-restricted diet at the expense of cornstarch on a weight-for-weight basis. The total amount
of added LNAA in the LNAA supplemented diet was equal to the amount of protein in the basal
AIN-93M diet (124.12 g/kg diet), consisting of different amounts of the various LNAA. This worked
out towards a composition of supplemented LNAA consisting of: l-tyrosine (28%), l-tryptophan (17%),
l-valine (14%), l-isoleucine (14%), l-leucine (14%), l-methionine (6%), l-histidine (3%), and l-threonine
(3%), as previously described and used [9]. If compared to a mean natural protein intake in humans of
1 g/kg body weight/d, this corresponds to approximately 280, 170, 140, 140, 140, 60, 30, and 30 mg/kg
body weight/d, respectively, in humans. Diets were prepared by Research Diet Services B.V. (Wijk bij
Duurstede, The Netherlands). Results of amino acid analyses in the different diets are presented in
Supplemental Table S1.
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Figure 1. Protein contents of the various experimental diets. The dashed line indicates the total protein
content of the AIN-93M control diet.
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2.4. Biochemical Analyses
To obtain brain material for biochemical analyses, whole brains were removed and divided into
cerebrum and cerebellum. The collected brain samples were all individually snap frozen in liquid
nitrogen and stored at –80 ◦C until further preparation. Frozen cerebrum was crushed in liquid nitrogen
and divided into aliquots. Frozen brain powder for amino acid measurements was processed to 20%
(weight: volume (w:v)) homogenates in phosphate-buffered saline (pH 7.4), and for tryptophan, indole
and catecholamine measurements to 2% (w:v) homogenates in acetic acid (0.08 M). Brain homogenates
were sonified on ice at 11–12 W, centrifuged at 800 rcf for 10 min (4 ◦C), and the supernatant/internatant
was placed on ice until further analysis. Samples were vortexed and centrifuged at 20.800 rcf for 4 min.
For brain and plasma amino acid (except for tryptophan) measurements, norleucine in sulfosalicylic
acid was added as an internal standard to the 20% brain homogenate (1:1, v:v) or to 50 µL plasma.
Amino acid concentrations were measured with a method based on ion exchange chromatography
with post-column derivatization with ninhydrin on a Biochrom 30+ analyser (Pharmacia Biotech,
Cambridge, UK).
For tryptophan and monoaminergic neurotransmitter measurements, an anti-oxidative solution
was prepared in demineralised water (0.4 g/L ascorbic acid and 1.616 g/L ethylenediaminetetraacetic
acid). For tryptophan and indole measurements, 25 µL of the anti-oxidative solution was added to
25 µL of the 2% brain homogenate. For catecholamine measurements, 40 µL of the anti-oxidative
solution was added to 10 µL of the 2% brain homogenate. Plasma tryptophan measurements
were performed using 25 µL plasma instead of 2% brain homogenate. Analysis of tryptophan and
monoaminergic neurotransmitter concentrations was performed using liquid chromatography in
combination with isotope dilution mass spectrometry, essentially as described by Van de Merbel
et al. [26]. Monoamines and associated metabolites for which brain concentrations were assessed
included dopamine, norepinephrine, 3-methoxytyramine, and normetanephrine in the catecholamine
pathway, and serotonin and 5-hydroxyindoleacetic acid (5-HIAA) in the serotonergic pathway.
2.5. Statistical Analyses
Statistical analyses were performed using the software IBM SPSS Statistics for Windows, Version
24.0 (Armonk, NY: IBM Corp.). All tests were performed two-sided at a significance level of α = 0.05.
The effect of dietary treatment on body weight and food intake was analyzed on log-transformed data
by two-way analysis of variance (ANOVA) and Tukey’s post hoc analysis with experimental group and
sex as independent variables. Brain and plasma biochemistry were analyzed by one-way ANOVA and
Tukey post hoc analyses on log-transformed data to induce normal distribution. In case of abnormally
distributed data after log-transformation (assessed by the Shapiro–Wilk test) or unequal variances
(assessed by Levene’s test), analyses were performed by Kruskal–Wallis tests and Mann–Whitney U
post hoc analyses.
3. Results
3.1. General Health and Dietary Intake
All experimental diets were well tolerated by the mice, as determined by general behaviour, body
weight and food intake. The median age of the mice at the start of the experiment did not significantly
differ between experimental groups (p = 0.76), being 55 weeks for all experimental groups (with a
minimum varying from 46–55 in the different experimental groups and a maximum of 70 weeks).
Figure 2 shows body weights of PKU and WT mice during the six weeks dietary treatment, separated
for male and female mice. At the start of the experiment, body weight was significantly lower for
female than for male mice (p < 0.01) and significantly lower for PKU than for WT mice (p < 0.01),
but they did not significantly differ between PKU mice in the different experimental groups. At the end
of the experiment, body weight was significantly lower in PKU mice on a less severe Phe-restricted diet
with or without LNAA supplementation compared with a severe Phe-restricted diet (p < 0.05), but not
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significantly different between WT and PKU mice in each of the experimental groups. Food intake in
each of the groups was highest during the first week, lowest during the second week, and relatively
stable from the 3rd week of treatment onwards (Supplemental Figure S1) Mean food intake during
these final weeks of treatment was significantly lower in WT mice than in each of the experimental
groups with PKU mice (p < 0.001). Also, food intake was significantly lower in female than in male
mice (p < 0.001) without a significant interaction between sex and experimental group (p = 0.64).
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Figure 2. Mean body weights in male (A) and female (B) wild-type (WT) and phenylketonuria (PKU)
mice on various diets during the six weeks of dietary treatment. Numbers of mice are n = 5 for all
experimental groups. Untransformed data are expressed as mean ± standard error of the mean (SEM).
3.2. Brai Monoamines
Brain monoaminergic neurotransmitter and associated metabolite concentrations in PKU mice
on the various experimental diets as well as in WT mice on AIN-93M diet are shown in Figure 3.
Brain dopa i e nd 3-methoxytyramine concentrations did not significa tly differ between any of
the experimental groups. Brain norepinephrine, serotonin, normetanephrine, and 5-HIAA, however,
were all significantly i paired in PKU mice on the less severe Phe-restricted diet when compared
to WT mice, a d improved or even c m letely restored n both the less severe Phe-restricted diet
+ LNAA as well as o the severe Phe-restricted diet. The cerebral deficiencies of norepinephrine
and normetanephrine in PKU ice on the less severe Phe-restricted diet, eing 66% (p < 0.001) and
80% (p < 0.01) of concentrations in WT mice on the AIN-93M diet, respectively, were restored to
c ncentrations that did no lo ger significantly differ from WT concentrations on both the less severe
Phe-restricte diet + LNAA (p = 0.449 and p = 0.10, respectively) and the severe Phe-restricted diet
(p = 0.690 and p = 0.95, respectively). In addition, the cerebral deficiencies of brain serotonin and
5-HIAA in PKU mice on the less severe Phe-restricted diet, being, respectively, 58% (p < 0.001) and
37% (p < 0.001) of concentrations in WT mice on AIN-93M diet, were improve to 81% and 52% of
conce trations in WT mice on the less severe Phe-restricted diet + LNAA, and to 90% and 60% of
concentratio s in WT mice on the severe Phe-restricted diet.
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Figure 3. Brain concentrations of (A) dopamine, (B) norepinephrine, (C) serotonin, (D) 3-methoxytyramine,
(E) normetanephrine, and (F) 5-hydroxyindoleacetic acid (5-HIAA) in WT and PKU mice after six weeks
of receiving various diets. Numbers of mice are n=10 for all experimental groups. Untransformed data
are expressed as mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001 (two-sided). For comparison, dashed
lines represent mean brain monoamine concentrations obtained in C57Bl/6 PKU mice on AIN-93M
diet in previous experiments [9,23]. Previously obtained mean brain monoamine concentrations in
PKU mice on the AIN-93M diet were expressed as proportion of data in respective WT mice and then
multiplied by mean brain monoamine concentrations of WT mice in the present study.
3.3. Brain Large Neutral Amino Acids (LNAA)
Brain concentrations of individual LNAA in PKU mice on the various experimental diets as well
as in WT mice on AIN-93M diet are shown in Figure 4. Brain Phe concentrations in PKU mice on all
of the experimental diets were significantly higher than in WT mice (p < 0.01). When comparing the
different experimental diets in PKU mice to one another, brain Phe concentrations in PKU mice on
the less severe Phe-restricted diet + LNAA and on the severe Phe-restricted diet were 85% and 49%,
respectively, of those in PKU mice on the less severe Phe-restricted diet without LNAA (p < 0.05 and
p < 0.001).
Brain concentrations of other LNAA all showed different responses to the various experimental
diets in PKU mice. Brain tyrosine and tryptophan concentrations were significantly lower in PKU
mice on the various Phe-restricted diets compared with WT mice, and did not improve on LNAA
supplementation. Brain methionine concentrations in PKU mice on both the less severe Phe-restricted
diet and the severe Phe-restricted diet were significantly lower compared with WT mice (p < 0.01 and
p < 0.05, respectively), but not when LNAA were supplemented (p = 0.43). In contrast, brain threonine
concentrations were significantly lower in PKU mice on the less severe Phe-restricted diet + LNAA
compared with both Phe-restricted diets without LNAA supplementation as well as with WT mice
(p < 0.01), while brain histidine concentrations were significantly higher in PKU mice on a less severe
Phe-restricted diet compared with all other treatment groups (p < 0.05).
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Figure 4. Brain concentrations of (A) phenylalanine, (B) tyrosine, (C) tryptophan, (D) valine, (E) isoleucine,
(F) leucine, (G) methionine, (H) histidine, and (I) threonine in WT and PKU mice after six weeks of
receiving various diets. Numbers of mice are n = 10 for all experimental groups. Untransformed data
are expressed as mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001 (two-sided). For comparison, dashed
lines represent mean brain amino acid concentrations obtained in C57Bl/6 PKU mice on AIN-93M diet
in previous experiments [21,23]. Previously obtained mean brain amino acid concentrations in PKU
mice on AIN-93M diet were expressed as proportion of data in respective WT mice and then multiplied
by mean brain amino acid concentrations of WT mice in the present study.
3.4. Plasma LNAA
Plasma concentrations of individual LNAA in PKU mice on the various experimental diets as well
as in WT mice on AIN-93M diet are shown in Figure 5. Plasma Phe concentrations in PKU mice on
each of the experimental diets were significantly higher than in WT mice on AIN-93M diet (p < 0.001).
Plasma Phe concentrations were significantly lower on the severe Phe-restricted diet if compared to
both less severe Phe-restricted diets (p < 0.001), but they did not significantly differ between the less
severe Phe-restricted diet with and without LNAA supplementation.
Plasma concentrations of other LNAA did not significantly differ between PKU mice on one of
the experimental diets and WT mice on the AIN-93M diet except for plasma tyrosine concentrations
that were significantly lower in PKU mice on the less severe Phe-restricted diet (p < 0.01) and plasma
threonine concentrations that were significantly lower in PKU mice on the less severe Phe-restricted
diet + LNAA compared to WT mice (p < 0.001). While plasma concentrations in PKU mice on the
less severe Phe-restricted diet + LNAA tended to be higher compared to both Phe-restricted diets
without LNAA supplementation, for some of the LNAA this was only statistically significant for
methionine (p < 0.01). In contrast, in PKU mice on the less severe Phe-restricted diet + LNAA, plasma
tryptophan concentrations were significantly lower than on the corresponding diet without LNAA
Nutrients 2019, 11, 2252 8 of 14
supplementation (p < 0.05), while plasma threonine concentrations were significantly lower compared
to both Phe-restricted diets without LNAA supplementation (p < 0.01).
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Figure 5. Plasma concentrations of (A) phenylalanine, (B) tyrosine, (C) tryptophan, (D) valine,
(E) isoleucine, (F) leucine, (G) methionine, (H) histidine, and (I) threonine in WT and PKU mice
after six weeks of receiving various diets. Numbers of mice are n = 10 for all experimental groups.
Untransformed data are expressed as mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001 (two-sided).
For comparison, dashed lines represent mean plasma amino acid concentrations obtained in C57Bl/6
PKU mice on the AIN-93M diet in previous experiments [21,23]. Previously obtained mean plasma
amino acid concentrations in PKU mice on the AIN-93M diet were expressed as proportion of data in
respective WT mice and then multiplied by mean plasma amino acid concentrations of WT mice in the
present study.
4. Discussion
Responding to the fact that, especially adult, PKU patients often cannot adhere to the severe
Phe-restricted diet well enough to ensure their plasma Phe concentrations are within the recommended
target range [25], and building on our previous studies on LNAA treatment in PKU mice, the
present study aimed to determine the possible benefit of LNAA supplementation to a less severe
Phe-restricted diet on plasma and brain amino acid and brain neurotransmitter concentrations in
comparison to a severe Phe-restricted diet in adult PKU mice. The two most important findings
of this study were that, when LNAA supplementation was added to a less severe Phe-restricted
diet: (1) brain norepinephrine and serotonin concentrations significantly increased and brain Phe
concentrations reduced, and (2) brain norepinephrine and serotonin concentrations were equally
effectively restored, but brain Phe concentrations were less effectively reduced when compared to a
severe Phe-restricted diet.
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Before discussing these results in further detail, we address some methodological issues. Firstly,
this study was performed in 10- to 16-month-old PKU mice as a model for (late-)adult PKU patients.
Although it should be noted that these results obtained in PKU mice cannot directly be translated to the
clinical setting, our previous studies showed that the PKU mouse provides a good model to investigate
the brain biochemical effects of LNAA treatment in PKU [8,23]. Also, of particular advantage in
the present study, such a mouse model is not subject to bias of differences in compliance between
dietary treatments. Secondly, the (less) severe Phe-restricted diets used here were designed to be
nutritionally adequate with the synthetic Phe-free amino acid mixture, compensating for the natural
protein restriction. In clinical practice, however, if patients themselves liberalize their Phe-restricted
diet, this compensation may not always be the case. Thirdly, we did not include PKU mice on an
unrestricted and non-supplemented (AIN-93M) diet in this study, but used the results on brain and
plasma amino acid and brain monoamine concentrations in young and adult C57Bl/6 PKU mice on
such a diet from our previous studies that showed consistent results [9,23]. To enable comparison,
we added those previously reported data to Figures 3–5 (dashed lines).
The present study showed that substituting the synthetic Phe-free amino acid mixture for
LNAA supplementation in PKU mice on a less severe Phe-restricted diet significantly increased brain
norepinephrine and serotonin, and reduced brain Phe concentrations. In line with the concept of
LNAA treatment, the less severe Phe-restricted diet + LNAA differed from the corresponding diet
without LNAA treatment with respect to both the total amount and composition of the amino acids
being supplemented [13,23]. Previous studies in PKU mice showed that the particular effectiveness
of LNAA treatment to improve brain monoamine concentrations is due to its combined effects of
reducing brain Phe and increasing precursor (tyrosine and tryptophan) availability [8,23]. In addition,
based on their findings on peripheral monoaminergic neurotransmitter markers in response to LNAA
supplementation in PKU patients, Yano et al. suggested that for serotonergic neurotransmitters the
effect of brain Phe seems to be most important, while for dopaminergic neurotransmitters the effect
of tyrosine availability seems to be the most important [22,27]. Following this hypothesis, the here
used LNAA supplement was primarily enriched in tyrosine, tryptophan, and the branched-chain
amino acids. Besides, all other non-Phe LNAA were supplemented as well, including methionine that
has been associated with increased tetrahydrobiopterin (BH4) levels and thereby might contribute to
increased brain monoaminergic neurotransmitter synthesis as well [28,29]. This LNAA supplementation
regimen, when added to a less severe Phe-restricted diet in PKU mice, effectively increased brain
norepinephrine and serotonin, and reduced brain Phe concentrations, while brain tyrosine and
tryptophan concentrations were not increased. This discrepancy with previous findings might
be explained by the fact that in previous LNAA studies that required both reduced brain Phe and
increased brain tyrosine and tryptophan availability for optimal improvement of brain neurotransmitter
concentrations, LNAA were added to an unrestricted instead of a less severe Phe-restricted diet, so
that brain Phe concentrations were higher [8,9,23]. Interestingly, and in accordance with previous
studies [8,9,23], brain concentrations of norepinephrine were significantly impaired in PKU mice and
could be effectively increased on LNAA treatment, while brain dopamine concentrations remained
largely unaffected. An explanation for these findings might be that phenethylamine, the monoamine
derivative of Phe, is a competitive inhibitor of norepinephrine synthesis [30]. Furthermore, our results
are also in accordance with findings in tyrosine hydroxylase-deficient mice in which norepinephrine is
also largely impaired and at earlier age compared with dopamine, suggesting that the homeostasis
mechanisms for dopamine synthesis, degradation and release are more strictly controlled than those
for norepinephrine [31]. At least, the combination of findings in the different LNAA studies shows
that the relationship between brain Phe, tyrosine, tryptophan and neurotransmitter concentrations in
PKU is complex and warrants further investigation. While the exact relationships between plasma
LNAA, brain LNAA, and brain neurotransmitters remain to be established, both brain Phe and
neurotransmitters have been ascribed to be important for brain functioning in PKU [32]. Based on
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these associations, our results at least suggest that cerebral outcome of PKU patients treated with a less
severe phenylalanine-restricted diet may be helped by additional LNAA treatment.
When it comes to treating adults with PKU, one of the main issues is the question of how the effects
of treatment relate to the associated treatment burden. Both the European and US guidelines on PKU
management advocate lifelong treatment, but differ with respect to the upper target plasma Phe levels
for adult PKU patients as the primary therapeutic target [1,33]. Many adult PKU patients cannot adhere
to the severe Phe-restricted diet and liberalize their diet, resulting in plasma Phe concentrations clearly
above the target levels of both guidelines [10,11]. Comparing the LNAA supplemented less severe
Phe-restricted diet with the severe Phe-restricted diet in view of their treatment effects, both treatments
were similarly effective in restoring brain neurotransmitter concentrations (that can be considered to
be the most important brain biochemical parameter of PKU symptoms in adults), while the severe
Phe-restricted diet was most effective to reduce brain Phe concentrations (that is often considered to
be the most important brain biochemical parameter to PKU symptoms in children). With regard to
the associated treatment burden, the severity of natural protein restriction (usually considered the
most burdensome aspect of the current dietary treatment) in the less severe Phe-restricted diet with
LNAA was only about 44% of the severity of the natural protein restriction in the severe Phe-restricted
diet, while the amount of amino acid supplementation (as essential amino acid mixture and LNAA
supplementation) was “only” increased by 11% compared to that in the severe Phe-restricted diet.
Taken together, LNAA supplementation to a less severe Phe-restricted diet thus seems to provide
a favorable alternative to the severe Phe-restricted diet for those PKU patients who cannot keep
their plasma Phe concentrations within the recommended target range. When comparing the results
obtained with LNAA supplementation to a less severe Phe-restricted diet in the present study to those
with LNAA supplementation to an unrestricted diet in previous studies [8,9], both applications of
LNAA treatment seem to be similarly effective. This also accounts for the plasma Phe concentrations,
as plasma Phe concentrations in PKU mice on a less severe Phe-restricted diet with LNAA were
comparable to those on LNAA supplementation to an unrestricted diet in a previous study. Therefore,
further studies should determine the possible additive effect of a less severe Phe-restricted diet to
LNAA treatment.
Previous studies in PKU mice demonstrated that the opposing effects on Phe, tyrosine,
and tryptophan concentrations in plasma and the brain are key to the success of LNAA treatment.
While the present study also showed that LNAA supplementation to a less severe Phe-restricted diet
could effectively improve brain monoaminergic neurotransmitters, such an effect on brain tyrosine and
tryptophan was not observed. At the same time, however, data also showed that the improved brain
monoaminergic neurotransmitter concentrations were not solely due to the effect on brain (nor plasma)
Phe concentrations (Supplemental Figure S2). Thereby, these results urge for (1) further studies
on the complex system of amino acids and monoaminergic neurotransmitters in PKU and (2) the
identification of alternative biomarkers that better correlate to brain monoaminergic neurotransmitter
concentrations to be used for monitoring of treatments that do not primarily work by reducing plasma
Phe concentrations such as LNAA supplementation. This also accounts for the relationship between
plasma LNAA and brain Phe concentrations. In the present study, brain Phe concentrations were
significantly reduced on LNAA supplementation to a less severe Phe-restricted diet, while plasma
Phe concentrations were unchanged. In contrast, plasma tyrosine, branched-chain amino acid, and
methionine concentrations were all increased. The most interesting in this is that plasma methionine
concentrations increased a lot. Even more interesting, however, is the fact that this seems to be
only one factor that influences the brain LNAA levels. Whether this means that there are other
mechanisms than LAT1 and B0AT1 important in the exchange of LNAA from blood to brain remains
to be understood. Moreover, the effects of LNAA treatment on threonine concentrations have not been
fully understood either. Threonine concentrations in both plasma and brain were significantly reduced
on the LNAA-supplemented compared to the non-supplemented less severe Phe-restricted diet despite
inclusion of threonine in the LNAA supplement. Previously investigated LNAA supplementation
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regimens with higher threonine dosage showed strongly increased threonine concentrations in both
plasma and brain [8], suggesting that threonine metabolism is a highly sensitive system. While the
significance of these alterations in threonine concentrations (on LNAA treatment) in PKU requires
further investigation, at least in the present study, brain serine and glycine concentrations were not
affected by the reduced threonine concentrations.
In view of a clinical application of LNAA treatment in PKU, the current finding in PKU mice
that LNAA supplementation to a less severe Phe-restricted diet could improve brain biochemistry,
supports previous data that LNAA supplementation could offer a promising treatment strategy to
improve neurocognitive and psychosocial outcomes in adult PKU patients [19–21]. Because of the
large number of, especially, adults with PKU who cannot adhere to the severe dietary restrictions
resulting in plasma Phe concentrations above the recommended target range, and the importance of
brain neurotransmitter impairments to their symptoms, LNAA treatment can be expected to offer a
real health benefit especially for adults with PKU. Another relatively new dietary treatment modality
for PKU that shares some of these principles with LNAA treatment, and that has already proven its
value in clinical practice, includes glycomacropeptide (GMP) [34,35]. Similar to LNAA treatment,
GMP provides an alternative to the original Phe-free amino acid mixture [36]. In contrast, where
GMP exploits the benefits of a palatable and low-Phe intact protein [37], LNAA treatment does not
bring the benefits of an intact protein source but is shown to be able, based on its specific composition,
to improve brain biochemistry. To further increase the effectiveness and tolerability of LNAA treatment,
future research should try to optimize LNAA treatment so that (1) it can further reduce brain Phe
concentrations in addition to its (already optimal) effect on brain neurotransmitters, and (2) it will
require a smaller total amount of LNAA to be supplemented. In relation to the latter, the effects of
a possibly increased amino acid load to renal functioning, exerted by LNAA treatment, deserves
further attention [38,39]. Another possible future treatment target for PKU that was only recently
investigated in a preclinical setting and shares some pathophysiological concepts with LNAA treatment
involves blockage of the SLC6A19 transporter which is responsible for intestinal uptake as well as renal
reabsorption of amino acids, especially of LNAA. Blockage of this transporter in a PKU mouse model
induced hyperaminoaciduria and selective reduction of plasma as well as brain Phe concentrations,
while plasma and brain concentrations of other amino acids were relatively unaffected [40]. At least
in theory, SLC6A19 blockage and LNAA treatment offers a promising treatment combination that
deserves further research.
5. Conclusions
To conclude, the present study aimed at determining the added/protective value of LNAA
supplementation to a less severe Phe-restricted diet on plasma and brain amino acid and
neurotransmitter concentrations in comparison to a severe Phe-restricted diet in adult PKU mice.
Thereby, it responds to the fact that many adult PKU patients cannot adhere to the severe dietary
restrictions and builds on our previous studies on LNAA treatment in PKU mice. This study
demonstrated that LNAA supplementation to a less severe Phe-restricted diet improved brain
neurotransmitter and Phe concentrations. Compared to a severe Phe-restricted diet, it was equally
effective to restore brain norepinephrine and serotonin concentrations even being less effective to
reduce brain Phe concentrations. These results make LNAA supplementation a promising treatment
strategy to improve neuropsychological outcomes in adults with PKU who have liberalized their
Phe-restricted diet.
This treatment approach, combining a less-aggressive Phe restriction with LNAA supplementation,
might be seen as an avenue for future research. During recent years, many new drug treatment
strategies have been proposed in PKU patients, including various forms of gene therapy and some are
really very promising (Lichter-Koncieki and Vockley 2019). Yet, all those have their own drawbacks,
either financial, not for all patients, safety concerns, need for other co-medicine etc. In addition to this,
understanding the phenomenon of dietary supplementation of the correct amino acids in the optimal
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dose might not only help PKU but also the treatment of other patient groups with a defect in amino
acid metabolism.
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